Claims for Patent: 8,017,758

Summary for Patent: 8,017,758

Title:	PNA oligomers, oligomer sets, methods and kits pertaining to the detection of Bacillus anthracis
Abstract:	This invention is related to novel PNA probes, probe sets, methods and kits pertaining to the determination of Bacillus anthracis.
Inventor(s):	Stender; Henrik (Gentofte, DK), Hyldig-Nielsen; Jens J. (Holliston, MA)
Assignee:	Boston Probes, Inc. (Bedford, MA)
Application Number:	10/393,855
Patent Claims:	1. A PNA oligomer comprising a probing nucleobase sequence that is at least ninety percent homologous to a nucleobase sequence, or its complement, selected from the group consisting of: CCA-SSG-GTA-TCD-DTC (Seq. ID No. 1) and TTC-AAA-GGC-TCC-CGC (Seq. ID No. 2). 2. The PNA oligomer of claim 1, wherein the probing nucleobase sequence is one hundred percent homologous to one of Seq. ID No. 1 or Seq. ID No. 2, or their complements. 3. The PNA oligomer of claim 1, wherein the oligomer is unlabeled. 4. The PNA oligomer of claim 1, wherein the oligomer is labeled with at least one detectable moiety. 5. The PNA oligomer of claim 4, wherein the detectable moiety or moieties are each independently selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound. 6. The PNA oligomer of claim 5, wherein the enzyme is selected from the group consisting of alkaline phosphatase, soybean peroxidase, horseradish peroxidase, ribonuclease and protease. 7. The PNA oligomer of claim 5, wherein the hapten is selected from the group consisting of fluorescein, biotin, 2,4-dinitrophenyl and digoxigenin. 8. The PNA oligomer of claim 1, wherein the oligomer is labeled with at least two independently detectable moieties. 9. The PNA oligomer of claim 8, wherein the two or more independently detectable moieties are independently detectable fluorophores. 10. The PNA oligomer of claim 1, wherein the oligomer comprises a non-fluorescent quencher moiety. 11. The PNA oligomer of claim 1, wherein the oligomer comprises an energy transfer set of labels. 12. The PNA oligomer of claim 1, wherein the oligomer is support bound. 13. A PNA oligomer that: a) comprises one or more non-natural nucleobases comprising a sequence that is at least ninety percent homologous to a nucleobase sequence, or its complement, selected from the group consisting of: CCA-SSG-GTA-TCD-DTC (Seq. ID No. 1) and TTC-AAA-GGC-TCC-CGC (Seq. ID No. 2); b) does not substantially intra or inter molecularly self-hybridize; and c) sequence-specifically hybridizes to a region of the nucleic acid of Bacillus anthracis. 14. The PNA oligomer of claim 13, wherein the non-natural nucleobases are each independently selected from the group consisting of 2,6-diaminopurine, 2-thiouracil and 2-thiothymine. 15. The PNA oligomer of claim 13, wherein the oligomer is unlabeled. 16. The PNA oligomer of claim 13, wherein the oligomer is labeled with at least one detectable moiety. 17. The PNA oligomer of claim 16, wherein the detectable moiety or moieties are each independently selected from the group consisting of: a dextran conjugate, a branched nucleic acid detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester and a chemiluminescent compound. 18. The PNA oligomer of claim 17, wherein the enzyme is selected from the group consisting of alkaline phosphatase, soybean peroxidase, horseradish peroxidase, ribonuclease and protease. 19. The PNA oligomer of claim 17, wherein the hapten is selected from the group consisting of fluorescein, biotin, 2,4-dinitrophenyl and digoxigenin. 20. The PNA oligomer of claim 13, wherein the oligomer is labeled with at least two independently detectable moieties. 21. The PNA oligomer of claim 20, wherein the two or more independently detectable moieties are independently detectable fluorophores. 22. The PNA oligomer of claim 13, wherein the oligomer comprises a non-fluorescent quencher moiety. 23. The PNA oligomer of claim 13, wherein the oligomer comprises an energy transfer set of labels. 24. The PNA oligomer of claim 13, wherein the oligomer is support bound. 25. An oligomer set comprising two or more oligomers, at least one of which is a PNA oligomer comprising a probing nucleobase sequence that is at least ninety percent homologous to a nucleobase sequence, or its complement, selected from the group consisting of: CCA-SSG-GTA-TCD-DTC (Seq. ID No. 1) and TTC-AAA-GGC-TCC-CGC (Seq. ID No. 2). 26. A method comprising: a) contacting a sample, under suitable hybridization conditions, with at least one PNA oligomer comprising a probing nucleobase sequence that is at least ninety percent homologous to a nucleobase sequence, or its complement, selected from the group consisting of: CCA-SSG-GTA-TCD-DTC (Seq. ID No. 1) and TTC-AAA-GGC-TCC-CGC (Seq. ID No. 2); and b) detecting, identify and/or quantitating hybridization of the probing nucleobase sequence of a PNA oligomer to a target sequence within the nucleic acid of Bacillus anthracis and correlating the result with the presence, absence and/or quantity of Bacillus anthracis in the sample. 27. A kit comprising: a) one or more PNA oligomers comprising a probing nucleobase sequence that is at least ninety percent homologous to a nucleobase sequence, or its complement, selected from the group consisting of: CCA-SSG-GTA-TCD-DTC (Seq. ID No. 1), TTC-AAA-GGC-TCC-CGC (Seq. ID No. 2) and TTC-AAT-GGC-TCC-CGC (Seq. ID No. 3); and b) other reagents, instructions or compositions useful in performing an assay suitable for determining the presence, absence and/or quantity of the nucleic acid of Bacillus anthracis in a sample.

Details for Patent 8,017,758

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2022-03-21